Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings or view top-rated stocks.

1 analysts have issued 1-year price objectives for Eiger BioPharmaceuticals' shares. Their EIGR share price forecasts range from $48.00 to $48.00. On average, they predict the company's share price to reach $48.00 in the next year. This suggests a possible upside of 514.6% from the stock's current price.
View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts.

Eiger BioPharmaceuticals' stock was trading at $5.19 at the beginning of the year. Since then, EIGR stock has increased by 50.5% and is now trading at $7.81.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EIGR earnings forecast.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.20. The biotechnology company earned $4.09 million during the quarter, compared to analysts' expectations of $2.10 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 97.79% and a negative net margin of 672.48%. During the same period last year, the firm earned ($0.57) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger BioPharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (1.60%), Assenagon Asset Management S.A. (1.47%), Knott David M Jr (0.93%), Northern Trust Corp (0.89%), Goldman Sachs Group Inc. (0.58%) and DAVENPORT & Co LLC (0.52%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends.

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EIGR stock can currently be purchased for approximately $7.81.

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $343.38 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.